These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
419 related articles for article (PubMed ID: 34769050)
1. Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review. Rodríguez Plá M; Dualde Beltrán D; Ferrer Albiach E Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769050 [No Abstract] [Full Text] [Related]
2. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review. Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488 [No Abstract] [Full Text] [Related]
3. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071 [TBL] [Abstract][Full Text] [Related]
4. The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma. Tracz JA; Donnelly BM; Ngu S; Vojnic M; Wernicke AG; D'Amico RS J Neurooncol; 2023 May; 163(1):1-14. PubMed ID: 37086369 [TBL] [Abstract][Full Text] [Related]
5. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471 [TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with lung cancer and brain metastases: a propensity score-matched analysis. Yomo S; Oda K; Oguchi K J Neurosurg; 2023 Dec; 139(6):1628-1637. PubMed ID: 37243558 [TBL] [Abstract][Full Text] [Related]
7. Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis. Lee E; Chen X; LeCompte MC; Kleinberg LR; Hales RK; Voong KR; Forde PM; Brahmer JR; Markowski MC; Lipson EJ; Lee SH; Bydon A; Lo SL; Lubelski D; Redmond KJ J Neurosurg Spine; 2023 Aug; 39(2):278-286. PubMed ID: 37148233 [TBL] [Abstract][Full Text] [Related]
8. The dynamic duo: A narrative review on the synergy between stereotactic body radiotherapy and immunotherapy in lung cancer treatment (Review). Cheng SH; Tu KY; Lee HH Oncol Rep; 2024 Jul; 52(1):. PubMed ID: 38874014 [TBL] [Abstract][Full Text] [Related]
9. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. Chen Y; Gao M; Huang Z; Yu J; Meng X J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363 [TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302 [TBL] [Abstract][Full Text] [Related]
11. Local and distant brain control in melanoma and NSCLC brain metastases with concurrent radiosurgery and immune checkpoint inhibition. Le A; Mohammadi H; Mohammed T; Burney H; Zang Y; Frye D; Shiue K; Lautenschlaeger T; Miller J J Neurooncol; 2022 Jul; 158(3):481-488. PubMed ID: 35641840 [TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis. Kim PH; Suh CH; Kim HS; Kim KW; Kim DY; Aizer AA; Rahman R; Guenette JP; Huang RY Eur Radiol; 2021 Jun; 31(6):4114-4129. PubMed ID: 33241519 [TBL] [Abstract][Full Text] [Related]
13. Concurrent Administration of Immune Checkpoint Inhibitors and Single Fraction Stereotactic Radiosurgery in Patients With Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma Brain Metastases. Lehrer EJ; Kowalchuk RO; Gurewitz J; Bernstein K; Kondziolka D; Niranjan A; Wei Z; Lunsford LD; Fakhoury KR; Rusthoven CG; Mathieu D; Trudel C; Malouff TD; Ruiz-Garcia H; Bonney P; Hwang L; Yu C; Zada G; Patel S; Deibert CP; Picozzi P; Franzini A; Attuati L; Prasad RN; Raval RR; Palmer JD; Lee CC; Yang HC; Harmsen WS; Jones BM; Sharma S; Ahluwalia MS; Sheehan JP; Trifiletti DM Int J Radiat Oncol Biol Phys; 2023 Jul; 116(4):858-868. PubMed ID: 36690161 [TBL] [Abstract][Full Text] [Related]
14. Long-Term Intracranial Outcomes With Combination Dual Immune-Checkpoint Blockade and Stereotactic Radiosurgery in Patients With Melanoma and Non-Small Cell Lung Cancer Brain Metastases. Vaios EJ; Shenker RF; Hendrickson PG; Wan Z; Niedzwiecki D; Winter SF; Shih HA; Dietrich J; Wang C; Salama AKS; Clarke JM; Allen K; Sperduto P; Mullikin T; Kirkpatrick JP; Floyd SR; Reitman ZJ Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1507-1518. PubMed ID: 38097090 [TBL] [Abstract][Full Text] [Related]
15. Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis. Lu VM; Goyal A; Rovin RA; Lee A; McDonald KL J Neurooncol; 2019 Jan; 141(1):1-12. PubMed ID: 30392086 [TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibition and single fraction stereotactic radiosurgery in brain metastases from non-small cell lung cancer: an international multicenter study of 395 patients. Lehrer EJ; Khosla AA; Ozair A; Gurewitz J; Bernstein K; Kondziolka D; Niranjan A; Wei Z; Lunsford LD; Mathieu D; Trudel C; Deibert CP; Malouff TD; Ruiz-Garcia H; Peterson JL; Patel S; Bonney P; Hwang L; Yu C; Zada G; Picozzi P; Franzini A; Attuati L; Prasad RN; Raval RR; Palmer JD; Lee CC; Yang HC; Fakhoury KR; Rusthoven CG; Dickstein DR; Sheehan JP; Trifiletti DM; Ahluwalia MS J Neurooncol; 2023 Oct; 165(1):63-77. PubMed ID: 37889444 [TBL] [Abstract][Full Text] [Related]
17. A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer. Mattes MD; Eubank TD; Almubarak M; Wen S; Marano GD; Jacobson GM; Ma PC Clin Lung Cancer; 2021 Jul; 22(4):268-273. PubMed ID: 33608212 [TBL] [Abstract][Full Text] [Related]
18. Factors associated with radiation necrosis and intracranial control in patients treated with immune checkpoint inhibitors and stereotactic radiotherapy. Hall J; Lui K; Tan X; Shumway J; Collichio F; Moschos S; Sengupta S; Chaudhary R; Quinsey C; Jaikumar S; Forbes J; Andaluz N; Zuccarello M; Struve T; Vatner R; Pater L; Breneman J; Weiner A; Wang K; Shen C Radiother Oncol; 2023 Dec; 189():109920. PubMed ID: 37769968 [TBL] [Abstract][Full Text] [Related]
20. Impact of Systemic Therapy Type and Timing on Intracranial Tumor Control in Patients with Brain Metastasis from Non-Small-Cell Lung Cancer Treated With Stereotactic Radiosurgery. Singh SA; McDermott DM; Mattes MD World Neurosurg; 2020 Dec; 144():e813-e823. PubMed ID: 32956881 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]